[161Tb]Tb PSMA I&Tc([161Tb]Tb PSMA I&Tc) - 药物靶点：PSMA_在研适应症：转移性去势抵抗性前列腺癌_专利_临床

概要

基本信息

药物类型

多肽偶联核素、治疗用放射药物

别名-

靶点

PSMA

作用方式

抑制剂

作用机制

PSMA抑制剂(前列腺癌特异性膜抗原抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

转移性去势抵抗性前列腺癌

非在研适应症-

原研机构

Peter MacCallum Cancer Institute

在研机构

Peter MacCallum Cancer Institute

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

3

项与 [161Tb]Tb PSMA I&Tc 相关的临床试验

NCT07621692

/ Recruiting临床1期IIT

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T in Patients With Metastatic Castration-Resistant Prostate Cancer

This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its safety, dosimetry, biodistribution, pharmacokinetics, and preliminary efficacy in Taiwanese men with metastatic castration-resistant prostate cancer, and to inform future clinical trials.

开始日期2026-01-01

申办/合作机构

国立台湾大学医学院附设医院

NCT07208240

/ Recruiting临床1/2期IIT

Tb-PSMA-I&T Radionuclide Neo-Adjuvant Treatment in Patients With Locally Advanced Prostate Cancer Before Radical Prostatectomy: TbeforePROST Trial.

This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.

开始日期2025-08-12

申办/合作机构

Rabin Medical Center

NCT05521412

/ Recruiting临床1/2期IIT

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study

This clinical trial will evaluate the safety and efficacy of [161Tb]Tb -PSMA-I&T in men with metastatic castration-resistant prostate cancer (mCRPC).

开始日期2022-09-29

申办/合作机构

Peter MacCallum Cancer Institute

100 项与 [161Tb]Tb PSMA I&Tc 相关的临床结果

登录后查看更多信息

100 项与 [161Tb]Tb PSMA I&Tc 相关的转化医学

登录后查看更多信息

100 项与 [161Tb]Tb PSMA I&Tc 相关的专利（医药）

登录后查看更多信息

100 项与 [161Tb]Tb PSMA I&Tc 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性去势抵抗性前列腺癌	临床2期	澳大利亚	Peter MacCallum Cancer Institute	2022-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05521412 (VIOLET, ASCO2025)	临床1/2期	转移性去势抵抗性前列腺癌 PSMA-positive disease	30	Terbium-161[161Tb]Tb-PSMA-I&T	積糧醖願餘繭鏇齋壓遞(鬱構鏇艱鹹簾顧獵糧願) = 憲襯鏇製醖餘獵網蓋窪獵製糧餘觸觸壓艱憲鏇 (蓋鏇選顧蓋憲製鹹網糧, 51 ~ 85) 更多	积极	2025-05-30
VIOLET (SNMMI2024)	临床1/2期	转移性去势抵抗性前列腺癌	30	[161Tb]Tb-PSMA-I&T	構簾齋淵艱獵醖鹹艱網(築製襯網簾鏇製壓齋遞) = 製範淵觸鹽鹹鹽夢淵鏇網獵夢餘艱蓋顧餘積餘 (廠淵顧遞製鑰顧膚顧餘, 0.05) 更多	积极	2024-06-09